These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 22633839)

  • 21. [Similarity of biotechnology-derived drugs: regulatory framework and specificity].
    Prugnaud JL
    Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars: the 'future' of biologic therapy?
    Ranjan N; Mahajan VK; Misra M
    J Dermatolog Treat; 2011 Dec; 22(6):319-22. PubMed ID: 20666673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Host Cell Proteins: The Hidden Side of Biosimilarity Assessment.
    Mihara K; Ito Y; Hatano Y; Komurasaki Y; Sugimura A; Jones M; Liu H; Mai S; Lara-Velasco O; Bai L; Ketkar A; Adams M; Hirato T; Ionescu R
    J Pharm Sci; 2015 Dec; 104(12):3991-3996. PubMed ID: 26367379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.
    van Aerts LA; De Smet K; Reichmann G; van der Laan JW; Schneider CK
    MAbs; 2014; 6(5):1155-62. PubMed ID: 25517301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Registration of similar biological products--Singapore's approach.
    Poh J; Tam KT
    Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statistical methods for assessment of biosimilarity using biomarker data.
    Chow SC; Lu Q; Tse SK; Chi E
    J Biopharm Stat; 2010 Jan; 20(1):90-105. PubMed ID: 20077251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Industry and regulatory experience of the glycosylation of monoclonal antibodies.
    Read EK; Park JT; Brorson KA
    Biotechnol Appl Biochem; 2011; 58(4):213-9. PubMed ID: 21838794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
    Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
    Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmaceutical biotechnology products approved within the European Union.
    Walsh G
    Eur J Pharm Biopharm; 2003 Jan; 55(1):3-10. PubMed ID: 12551698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
    Walenga JM; Jackson CM; Kessler CM
    Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar medicines--new challenges for a new class of medicine.
    Fox A
    J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics.
    Hsieh TC; Chow SC; Yang LY; Chi E
    Stat Med; 2013 Feb; 32(3):406-14. PubMed ID: 22899403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccines and biosimilarity: a solution or a problem?
    Corbel MJ; Cortes Castillo Mde L
    Expert Rev Vaccines; 2009 Oct; 8(10):1439-49. PubMed ID: 19803764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing biosimilarity and interchangeability of biosimilar products.
    Chow SC
    Stat Med; 2013 Feb; 32(3):361-3. PubMed ID: 23307569
    [No Abstract]   [Full Text] [Related]  

  • 38. The regulatory framework of biosimilars in the European Union.
    Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
    Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
    Cai XY; Thomas J; Cullen C; Gouty D
    Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
    Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
    J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.